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THE PRESENCE of tumour specific
antigens in mammary carcinoma is now
well documented. Intracutaneous injec-
tion of antigens derived from autologous
and allogeneic mammary tumours pro-
duced specific delayed-type skin reactions
in some breast cancer patients, while
similarly prepared benign or normal
mammary tissue gave no response (Hughes
and Lytton, 1964; Stewart and Orizaga,
1971; Alford, Hollinshead and Herberman,
1973).
The leucocyte migration test of S0berg
and Bendixen (1967) has proved the most
useful in vitro technique for the demon-
stration of tumour-specific antigens in
breast carcinoma (Andersen et al., 1970;
Segall et al., 1972; Cochran et al., 1972,
1973), these workers showing that extracts
of mammary tumour, but not extracts of
benign or normal breast tissue, inhibited
the migration of autologous and allogeneic
patients' leucocytes. Tne present study
uses the test in the presence of autologous
and allogeneic breast cancer extracts and
of cell membrane preparations, with the
addition of follow-up tests.
MATERIALS AND METHODS
All the patients studied form part of an
ongoing clinical trial designed to identify the
immunological patterns of patients under-
going simple mastectomy and lymph node
biopsy.
Tumour extracts were prepared from hand
homogenized tissue by the method of
Andersen et al. (1970), and extracts were also
further processed by centrifugation at 3000 g
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(Wolf, 1969) to give a sediment of cell ghosts
(membranes). The protein concentration of
these preparations was adjusted to 2 mg/ml
and antigens were stored frozen in small
aliquots until needed. For in vitro tests, the
antigens were diluted intissue culture medium
199 containing 10% foetal calf serum,
NaHCO3 and antibiotics (199 + 10% FCS)
to 50, 100, 150 and 200 ,ug/ml.
Seven days after operation, membranes
and extract from each tumour were tested
against autologous and allogeneic breast
cancer patients' leucocytes and against cells
from healthy volunteers. Follow-up tests
of sensitivity to autologous antigen were
performed 8-12 weeks after operation.
Leucocytes were separated from heparin-
ized whole blood by sedimentation on Ficoll-
Triosil and were washed 3 times in 199 + 10%
FCS. The method used for leucocyte
migration was similar to that of Federlin
et al. (1971) except that 3 instead ofthe usual
2 capillaries, each containing 6 x 105 leuco-
cytes, were mounted within each migration
chamber. Migration indices (M.I.) for each
dilution of tumour antigen were calculated
as follows:
M.1. Average migration in tumour antigen
Av-erage migration in 199 + 10% FCS
RESULTS
Leucocyte migration results are sum-
marized in the Table. Writh very few
exceptions, M.I.s of control leucocytes
were within the 95%o confidence limits of
0-79-1-21; in contrast, leucocytes from
mammary carcinoma patients were in-
hibited (AI.T. < 0.79) in 8/34 cases byB. M. JONES AND A. R. TURNBULL
TABLE Leucocyte Migiration Inhibition (M.I. < 0.79) by Tumour C(ell Membranes and
Tumour Extract at 50, 100, 150 and 200 plg/ml in Normal Controls and in Autologous
and Allogeneic Mammiary Carcinoma Patients
Membranes (,ug/ml) Extract (,ug/ml)
Leucocyte migration ,- - Total , - - Total
inhibition 50 100 150 200 A-ive 50 100 150 200 +ive
Control 0/24 1/37 0/27 2/27 3/37 0/33 0/37 1/37 2/37 2/37
Autologous 0/24 5/34 7/25 S
Allogeneic 0/21 4/30 7/22 8
autologous membranes, 4/34 by the autolo-
gous extract and 4/34 by both prepara-
tions. Total positivity was therefore
16/34 (47%0). Both the degree of migra-
tion inhibition and the number ofpositives
obtained increased with antigen concen-
tration.
Of the 16 patients positive to auto-
logous antigens, 11/14 tested were also
positive to allogeneic antigens, whereas
only 5/18 patients not sensitive to auto-
logous antigen were positive to allogeneic
tumour. This suggests that there are
common or cross-reacting antigens in
breast carcinoma and it is likely that
negative results were obtained because the
patient's lymphocytes were unable to
react to tumour in vitro and not because
of a loss of antigenicity during tumour
antigen preparation.
Twenty-seven of the patients have so
far been re-tested at 2 months after
operation. Four ofthe patients who were
positive to autologous tumour at 7 days
remained positive at follow-up; 11 were
positive initially but appeared to have
lost sensitivity by the time they were
re-tested; and 10 were negative on both
occasions. Two of the patients have
become positive after giving an initially
negative result.
DISCUSSION
Sensitivity to autologous breast cancer
antigens has been demonstrated in 16/34
(47%o) patients, which compares with 8/22
(36%o) in the report of Andersen et al.
(8%)
8/25 12/34
(36%)
8/22 13/30
(43%)
3/31 5/34 4/34 7/34
1/27 4/30 3/29 4/30
(5%)
8/34
(24%)
5/30
(17%)
(1970); 8/13 (62%), Segall et al. (1972) and
6/8 (75%o), Cochran et al. (1972).
Sixteen patients out of 30 tested
(5300) showed sensitivity to allogeneic
breast tumour antigens and in fact cross-
reactivity was observed in 7900 ofpatients
positive to autologous antigens. The
presence of cross-reacting antigens in
breast carcinoma might indicate a viral
influence in the aetiology of the disease
(Sinkovics, 1970) and although this hypo-
thesis remains to be substantiated, the
possibility of using viral antigens rather
than tissue-associated antigens might lead
to further progress in the development of
in vitro diagnostic and prognostic tests.
The selection of methods for prepara-
tion of tumour-specific antigens from
malignant tisstlie is clearly of considerable
importance. In our hands, tumour ex-
tracts (Andersen et al., 1970) inhibited
migration in 8/34 cases, whereas further
treatment of the extract to give a cell
membrane preparation increased the
number of positives to 12/34.
There appeared to be no significant
difference between the results of leucocyte
migration tests performed 7 days and
2 months after operation in 16 patients
selected for regional radiotherapy and
those of 11 patients receiving no post-
operative treatment, but it is of interest
to note that 8 of the 13 patients with
histological evidence of axillary lymph
node involvement were positive when
tested 7 days after operation but had lost
sensitivity by the 2 month test, whereas
only 3/12 patients without metastases
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reacted in this way. The probability of
there being a significant difference between
these two groups of patients was 0 15 (X2
with Yates' correction).
The preliminary results presented here
clearly await confirmation and extension.
It is possible that serial follow-uV tests
might provide useful prognostic informa-
tion and the presence of common or cross-
reacting antigens in breast cancer might
also indicate the usefulness of in vitro
diagnostic tests for which pooled tumour
membrane antigens might be employed.
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